MS patients receiving aCD20 treatment mount robust T-cell responses to COVID-19 vaccines

By | September 15, 2021
New research shows that Multiple Sclerosis (MS) patients undergoing anti-CD20 (aCD20) treatment – which depletes the B cells that contribute to the MS attacks – are able to mount robust T-cell responses to the mRNA COVID-19 vaccines, despite having a muted antibody response to the vaccines.